StalkMedium
ALDX remains in an early/fragile Stage 1 consolidation base with accumulation signals from follow-through and exhaustion tags. Medium-term bias is bullish given the flattening 9/21 EMA regime and bottoming patterns, but price recently extended into resistance and is now pulling back. Short-term timing is neutral, so execution is deferred—stalking for pullbacks into the 9/21 EMA support zone.
- ↑Phase 3 Reproxilab reduced ocular discomfort (p=0.002), outperforming slow-acting rivals
- ↑Cash reserves >$100M support clinical programs into 2027 without dilutive financing
- ↓FY22 net loss of $62M increases funding risk as R&D expenses rise
Full analysis →